MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to detect drug and alcohol impairment in real time, offering a non-invasive alternative to traditional testing methods. The company's technology analyzes short speech samples, leveraging over 50 million data points and more than 140 acoustic markers to identify signs of intoxication. This approach could transform workplace safety screening, particularly in high-risk industries such as mining, aviation, construction, and transportation.
The platform is being developed for deployment through Edge AI kiosks, which process voice data locally to provide immediate results. Initial field testing is planned for 2026, with a commercial focus on South American mining operations, where large-scale workforce screening poses significant safety and logistical challenges. The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts, underscoring the demand for faster, scalable solutions.
MindBio's technology aims to address limitations of current methods, such as breathalyzers, saliva tests, and laboratory analyses, which can be time-consuming, invasive, or require specialized equipment. By using voice analysis, the company hopes to enable frequent, non-intrusive testing that can be integrated into daily operations. Beyond mining, the platform has potential applications in aviation, construction, transportation, law enforcement, call centers, and healthcare, where impairment detection is critical for safety and compliance.
For more details, view the full article at https://ibn.fm/Gw5Fa. Information about MindBio Therapeutics is available at https://ibn.fm/MBQIF.
